Country's Largest Distributors and Pharmacy Chains to Carry RESPeRATE
Hypertension Treatment Device
NEW YORK and MAROOCHYDORE, Australia, Oct. 1 /PRNewswire/ -- InterCure, Ltd. (TASE: INCR), today announced that its RESPeRATE(R) hypertension treatment device, clinically-proven in 10 published studies to significantly lower blood pressure, will launch into retail distribution in Australia through its local marketing and distribution partner, High Tech Health (HTH). RESPeRATE will be distributed through Australia's three largest pharmacy wholesalers into leading pharmacy chains nationwide, including Chemmart, Terry White and Think Pharmacy. This retail distribution partnership marks another key step in RESPeRATE's channel evolution, as it expands from a direct-to- consumer model to more traditional pharmacy channels globally.
High Tech Health will initially introduce RESPeRATE into 300 retail pharmacy locations in early Q4. HTH will leverage its network of merchandising specialists to ensure that each pharmacy staff person is well-trained in the use and benefits of RESPeRATE, to establish merchandising programs at the store level and to hold community patient education sessions on hypertension management and the use of RESPeRATE. HTH currently serves about 1,000 of the 5,000 pharmacies in Australia.
"This is great news for the millions of hypertension sufferers in Australia who seek a new option to help control their condition," said Erez Gavish, president and CEO of InterCure. "The vast majority of our prospective customers tell us that they would prefer to buy RESPeRATE at their local pharmacy. Our move into the Australian pharmacy channel will allow consumers to buy at their preferred retailer for health products, while building a strong retail presence for InterCure. This marks another key step in the Company's broad strategy of adding pharmacy distribution to our direct sales platform."
Almost one billion people worldwide have high blood pressure, including nearly one in three Australians. According to the National Heart Foundation of Australia, hypertension is the most frequently managed problem in general physician practices. Traditional treatment methods of diet, exercise and medication are often unable to help patients reach their lower blood pressure goals. Left untreated, high blood pressure may lead to heart attack, stroke and kidney or heart failure.
"RESPeRATE is a perfect fit within our health solutions portfolio of brands. It complements well our existing pharmacy product offerings, and we look forward to bringing our point of presence expertise to this innovative solution for hypertensives in Australia. Our focus on a high-touch retail approach, with a particular emphasis on pharmacy staff will surely establish RESPeRATE well with our pharmacy partners and their trusting customers," said Sam Penny, president of High Tech Health.
"We are excited to have the opportunity to introduce a clinically-proven, non-drug alternative to our customers to assist in the treatment of high blood pressure," said Sharon Bell of Think Pharmacy.
RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically-proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.
About InterCure, Ltd.
InterCure, a medical device company publicly traded on the Tel Aviv Stock Exchange (TASE: INCR) has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomic nervous system. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE(R), with more than 75,000 units sold. With multiple published clinical studies, regulatory clearance in most key international markets (including FDA over-the-counter ("OTC") clearance in the U.S., the European CE mark and the Chinese SDA among others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com)
About High Tech Health
High Tech Health is a privately owned company committed to improving the health of consumers through innovative medical devices and better education about drug-free alternatives. HTH is now Australia's leading supplier of OTC medical devices supplying almost 1,000 pharmacies as well as circulating its much acclaimed newsletter to nearly 50,000 subscribers.
HTH launched in the United Kingdom with New Zealand being established in early 2007 to follow the same commitment of its Australian operations; to create a range of medical devices that perform, provide results and are backed by clinical evidence. (http://www.hightechhealth.com.au)
This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
High Tech Health
|SOURCE InterCure, Ltd.|
Copyright©2007 PR Newswire.
All rights reserved